Ophthotech has entered into an exclusive global license agreement with the University of Florida Research Foundation and the University of Pennsylvania to develop and commercialize a novel adeno-associated virus gene therapy product to treat rhodopsin-mediated autosomal dominant retinitis pigmentosa, the company announced in a press release.
In addition, Ophthotech and Penn have also entered into a master sponsored research agreement to conduct preclinical and natural history studies, the release said.
Rhodopsin-mediated autosomal dominant retinitis pigmentosa, an orphan monogenic disease that
Uncategorized